» Articles » PMID: 25473898

Double-punching PMBL

Overview
Journal Oncotarget
Specialty Oncology
Date 2014 Dec 5
PMID 25473898
Authors
Affiliations
Soon will be listed here.
References
1.
Dunleavy K, Pittaluga S, Maeda L, Advani R, Chen C, Hessler J . Dose-adjusted EPOCH-rituximab therapy in primary mediastinal B-cell lymphoma. N Engl J Med. 2013; 368(15):1408-16. PMC: 4568999. DOI: 10.1056/NEJMoa1214561. View

2.
Hamlin P . Evolving treatment paradigms for primary mediastinal diffuse large B-cell lymphoma. J Clin Oncol. 2014; 32(17):1751-3. DOI: 10.1200/JCO.2014.55.2810. View

3.
Barth T, Leithauser F, Joos S, Bentz M, Moller P . Mediastinal (thymic) large B-cell lymphoma: where do we stand?. Lancet Oncol. 2002; 3(4):229-34. DOI: 10.1016/s1470-2045(02)00714-3. View

4.
Cerchietti L, Ghetu A, Zhu X, da Silva G, Zhong S, Matthews M . A small-molecule inhibitor of BCL6 kills DLBCL cells in vitro and in vivo. Cancer Cell. 2010; 17(4):400-11. PMC: 2858395. DOI: 10.1016/j.ccr.2009.12.050. View

5.
Ritz O, Rommel K, Dorsch K, Kelsch E, Melzner J, Buck M . STAT6-mediated BCL6 repression in primary mediastinal B-cell lymphoma (PMBL). Oncotarget. 2013; 4(7):1093-102. PMC: 3759668. DOI: 10.18632/oncotarget.1149. View